Did you know…If you have Parkinson’s disease, you have a higher risk of breaking any bones and you are 4 times more likely to have a hip fracture.
A team of Parkinson’s experts at UCSF are leading a study to investigate whether a medicine called zoledronic acid (ZA) can reduce fractures in people with Parkinson’s disease. The study is called TOPAZ, which stands for Trial Of Parkinson’s And Zoledronic Acid, and is being funded by the National Institute of Aging (part of the National Institutes of Health).
Zoledronic acid is an FDA approved treatment for osteoporosis (weak bones). We want to learn if it can help lower fracture risk in people with Parkinson’s Disease, whether or not they have osteoporosis. Clinical trials have shown that ZA reduces hip fractures by 40% and may decrease the risk of dying.
All parts of this study can be done from the comfort of the participant’s home. If you take part, you will be paid up to $200 for your time.
You can join if you…
Have Parkinson’s disease
Are 65 years or older
Have not had a hip fracture
Please click
here to watch a short video for more information about the study.
